Candel Therapeutics Income Statement Analysis
Values in millions USD
Scroll to see more
| Breakdown | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Period ending | Sep 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
| Revenue & Gross Profit | ||||||||
| Revenue | - | 0.00 | 0.00 | 0.00 | 0.13 | 0.13 | 0.13 | 0.13 |
| Cost of Revenue | - | 0.00 | 0.00 | 23.59 | 20.35 | 14.59 | 0.00 | 0.00 |
| Gross Profit | - | 0.00 | 0.00 | -23.59 | -20.22 | -14.47 | 0.13 | 0.13 |
| Operating Expenses | ||||||||
| Research & Development | 56.05 | 29.76 | 19.31 | 23.59 | 20.79 | 15.18 | 7.94 | 6.61 |
| Selling, General & Administrative | 25.71 | 18.42 | 14.06 | 14.41 | 14.50 | 11.26 | 5.99 | 2.56 |
| Operating Expenses | 81.69 | 48.18 | 33.37 | 38.00 | 14.50 | 11.26 | 13.94 | 9.16 |
| Operating Income | -81.69 | -48.18 | -33.37 | -38.00 | -34.72 | -25.73 | -13.81 | -9.04 |
| Other Income/Expense | ||||||||
| Interest Income | 5.91 | 3.92 | 1.09 | 2.08 | 1.22 | 0.00 | 0.11 | 1.07 |
| Interest Expense | 6.15 | 2.12 | 2.09 | -2.60 | -1.71 | -0.05 | 0.00 | 0.00 |
| Other Income/Expense | -17.52 | 10.08 | -20.80 | 0.45 | 15.93 | -10.40 | -3.98 | 0.80 |
| Income | ||||||||
| Income Before Tax | -99.14 | -38.18 | -55.18 | -37.94 | -18.79 | -36.12 | -17.68 | -8.24 |
| Income Tax Expense | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -99.14 | -38.18 | -55.18 | -37.94 | -18.79 | -36.12 | -17.68 | -8.24 |
| Net Income - Continuous Operations | -99.14 | -38.18 | -55.18 | -37.94 | -18.79 | -36.12 | -17.68 | -8.24 |
| Net Income - Discontinued Operations | - | - | - | - | - | - | - | - |
| EBITDA | -80.00 | -47.33 | -52.10 | -37.04 | -33.94 | -25.49 | -13.72 | -8.42 |
| EBIT | -80.65 | -48.18 | -53.09 | -38.00 | -34.72 | -25.73 | -13.81 | - |
| Depreciation & Amortization | 0.65 | 0.85 | 0.99 | 0.96 | 0.78 | 0.23 | 0.09 | 0.04 |
| Earnings Per Share | ||||||||
| Basic EPS | -1.48 | -0.72 | -1.74 | -1.31 | -0.65 | -1.91 | -2.00 | - |
| Diluted EPS | -1.48 | -0.72 | -1.74 | -1.31 | -0.65 | -1.91 | -2.00 | - |
| Basic Shares Outstanding | 67.19 | 52.96 | 31.68 | 28.94 | 28.82 | 18.87 | 11.62 | 18.71 |
| Diluted Shares Outstanding | 67.19 | 52.96 | 31.68 | 28.94 | 28.82 | 18.87 | 11.62 | 18.71 |
Source: Company financial statements from annual and quarterly filings. Data as of Sep 30, 2026. Data sources and methodology
